<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1207" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1207/" /><meta name="ncbi_pagename" content="Alport Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Alport Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Alport Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/02/21" /><meta name="citation_author" content="Clifford E Kashtan" /><meta name="citation_pmid" content="20301386" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1207/" /><meta name="citation_keywords" content="Familial Nephritis" /><meta name="citation_keywords" content="Hereditary Nephritis" /><meta name="citation_keywords" content="Thin Basement Membrane Disease" /><meta name="citation_keywords" content="Thin Basement Membrane Nephropathy" /><meta name="citation_keywords" content="Familial Nephritis" /><meta name="citation_keywords" content="Hereditary Nephritis" /><meta name="citation_keywords" content="Thin Basement Membrane Disease" /><meta name="citation_keywords" content="Thin Basement Membrane Nephropathy" /><meta name="citation_keywords" content="Collagen alpha-3(IV) chain" /><meta name="citation_keywords" content="Collagen alpha-4(IV) chain" /><meta name="citation_keywords" content="Collagen alpha-5(IV) chain" /><meta name="citation_keywords" content="COL4A3" /><meta name="citation_keywords" content="COL4A4" /><meta name="citation_keywords" content="COL4A5" /><meta name="citation_keywords" content="Alport Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Alport Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Clifford E Kashtan" /><meta name="DC.Date" content="2019/02/21" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1207/" /><meta name="description" content="In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is X-linked (XLAS); approximately 15% is autosomal recessive (ARAS), and approximately 20% is autosomal dominant (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare." /><meta name="og:title" content="Alport Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is X-linked (XLAS); approximately 15% is autosomal recessive (ARAS), and approximately 20% is autosomal dominant (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1207/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/alport/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1207/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8973CBE03FE041000000000B5A04E2.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1207_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1207_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/a-thal/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/alstrom/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1207_"><span class="title" itemprop="name">Alport Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Familial Nephritis, Hereditary Nephritis, Thin Basement Membrane Disease, Thin Basement Membrane Nephropathy</div><p class="contrib-group"><span itemprop="author">Clifford E Kashtan</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1207_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1207_ai__"><div class="contrib half_rhythm"><span itemprop="author">Clifford E Kashtan</span>, MD<div class="affiliation small">Department of Pediatrics<br />University of Minnesota<br />Minneapolis, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nmu.ct@100thsak" class="oemail">ude.nmu.ct@100thsak</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 28, 2001</span>; Last Update: <span itemprop="dateModified">February 21, 2019</span>.</p><p><em>Estimated reading time: 31 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="alport.Summary" itemprop="description"><h2 id="_alport_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> (XLAS); approximately 15% is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> (ARAS), and approximately 20% is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of Alport syndrome is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in <i>COL4A3</i>, <i>COL4A4</i>, or <i>COL4A5</i> identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker to delay onset of ESRD; routine treatment of hypertension; renal transplantation for ESRD. Potential living related donors must be evaluated carefully to avoid nephrectomy in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual. Routine treatment of SNHL and cataracts; surgical intervention for symptomatic leiomyomas.</p><p><i>Agents/circumstances to avoid:</i> Protection of corneas from minor trauma in those with recurrent corneal erosions. Minimize exposure to loud noise.</p><p><i>Surveillance</i>: Follow up of all individuals with Alport syndrome with a nephrologist every six to 12 months; monthly monitoring of at-risk transplant recipients for development of anti-glomerular basement membrane antibody-mediated glomerulonephritis for the first year post transplant; audiologic evaluation of children every one to two years beginning at age six to seven years; monitoring for ocular abnormalities; evaluation for aortic dilation (for males with XLAS).</p><p><i>Evaluation of relatives at risk:</i> Evaluate at-risk family members either by urinalysis or, if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known, by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Three modes of inheritance are recognized for Alport syndrome: <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a>, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>, and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p><ul><li class="half_rhythm"><div>In families with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance, mothers <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a 50% chance of transmitting the pathogenic variant in each pregnancy; sons who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with Alport syndrome and will eventually develop ESRD and, in most cases, deafness; daughters who inherit the pathogenic variant will typically have asymptomatic hematuria but may have more severe renal disease. Affected males will pass the pathogenic variant to all of their daughters and none of their sons.</div></li><li class="half_rhythm"><div>In families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance, the parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes and carry one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; at conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> who may or may not be symptomatic, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>In families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance, each child of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and being affected.</div></li><li class="half_rhythm"><div>In rare Alport families with <a class="def" href="/books/n/gene/glossary/def-item/digenic/">digenic</a> inheritance (pathogenic variants in two or more of the <i>COL4A3</i>, <i>COL4A4</i>, and <i>COL4A5</i> genes), transmission patterns may not conform to mendelian expectations.</div></li></ul><p>Molecular genetic testing for at-risk family members, prenatal testing for pregnancies at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known.</p></div></div><div id="alport.Diagnosis"><h2 id="_alport_Diagnosis_">Diagnosis</h2><p>Alport syndrome is a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> renal disorder caused by pathogenic variants in <i>COL4A3</i>, <i>COL4A4</i>, and <i>COL4A5</i> that result in abnormalities of the collagen IV &#x003b1;345 network of basement membranes [<a class="bk_pop" href="#alport.REF.kashtan.2018.1045">Kashtan et al 2018</a>]. Alport syndrome can be transmitted in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> (XLAS), <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> (ADAS), or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> (ARAS) pattern. The spectrum of renal involvement ranges from <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a>, non-progressive hematuria to progressive nephropathy characterized by hematuria, proteinuria, and chronic kidney disease (CKD) and end-stage renal disease (ESRD). Affected individuals often have sensorineural hearing loss and characteristic ocular abnormalities. Rare individuals have associated aortic disease or diffuse leiomyomatosis.</p><p>This definition differs from previous iterations in that it classifies individuals with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hematuria and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>COL4A3</i> and <i>COL4A4</i> as having ADAS, rather than so-called "thin basement membrane nephropathy." For the argument in favor of this approach see <a class="bk_pop" href="#alport.REF.kashtan.2018.1045">Kashtan et al [2018]</a>; for the counterargument see <a class="bk_pop" href="#alport.REF.savige.2018.1239">Savige [2018]</a>. The goals of this approach are:</p><ul><li class="half_rhythm"><div>To encourage establishment of specific diagnoses in individuals with persistent glomerular hematuria with molecular confirmation whenever possible;</div></li><li class="half_rhythm"><div>To facilitate surveillance of individuals with pathogenic variants in <i>COL4A3</i>, <i>COL4A4</i>, and <i>COL4A5</i> for evidence of renal disease progression;</div></li><li class="half_rhythm"><div>To promote early initiation of therapy to delay or prevent ESRD; and</div></li><li class="half_rhythm"><div>To improve identification of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members.</div></li></ul><div id="alport.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Alport syndrome <b>should be suspected</b> in an individual with the following clinical and <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> features [<a class="bk_pop" href="#alport.REF.kashtan.2004.1290">Kashtan 2004</a>].</p><p><b>Renal</b></p><ul><li class="half_rhythm"><div>Hematuria. 100% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males and more than 90% of affected females with XLAS have microhematuria (blood in the urine detectable only by microscope); 100% of males and females with ARAS have hematuria. Episodic gross hematuria is not unusual. Most individuals with ADAS have hematuria, although it may be intermittent.</div></li><li class="half_rhythm"><div>Proteinuria, hypertension, and renal insufficiency develop with advancing age in all males with XLAS and in all males and females with ARAS. Proteinuria is frequent in ADAS, especially with advancing age, and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may exhibit progressive renal disease. Pathogenic variants in <i>COL4</i> genes are not unusual in adult patients with proteinuria and renal biopsy findings of focal segmental glomerulosclerosis.</div></li></ul><p><b>Cochlear</b></p><ul><li class="half_rhythm"><div>Bilateral high-frequency sensorineural hearing loss (SNHL) typically becomes apparent by audiometry in late childhood or early adolescence in males with XLAS and in males and females with ARAS.</div></li><li class="half_rhythm"><div>In XLAS, SNHL eventually develops in 80%-90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males as well as in some affected females; the incidence of SNHL in males and females with ARAS is probably similar to that in males with XLAS.</div></li><li class="half_rhythm"><div>In some families with XLAS and in ADAS, SNHL may not be detectable until well into adulthood.</div></li></ul><p><b>Ocular</b></p><ul><li class="half_rhythm"><div>Anterior lenticonus is pathognomonic of Alport syndrome. It occurs in 15%-20% of those with XLAS or ARAS and typically becomes apparent in late adolescence or early adulthood.</div></li><li class="half_rhythm"><div>Perimacular flecks occur in approximately 30% of individuals with Alport syndrome.</div></li></ul><p><b>Family history</b></p><ul><li class="half_rhythm"><div>Family history positive for hematuria, deafness, and/or ESRD is frequently seen.</div></li><li class="half_rhythm"><div>Family history of hematuria or renal failure may be negative because 10%-15% of males with XLAS have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and approximately 15% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have ARAS.</div></li></ul></div><div id="alport.Testing"><h3>Testing</h3><div id="alport.Urinalysis"><h4>Urinalysis</h4><p><b>Males with XLAS; males and females with ARAS.</b> Urinalysis typically shows hematuria (dozens to hundreds of erythrocytes per high-power microscope field). Overlap with normal results is minimal. Proteinuria develops in essentially 100% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, although the timing is variable.</p><p><b>Female heterozygotes for XLAS.</b> Approximately 95% of heterozygotes exhibit persistent or intermittent microhematuria. Proteinuria develops in approximately 75% of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females.</p><p><b>Both males and females with XLAS</b> may have intermittent or constant gross hematuria.</p><p><b>Both males and females with ADAS.</b> Urinalysis frequently shows microhematuria although some individuals are asymptomatic. A substantial proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals eventually develop proteinuria.</p></div></div><div id="alport.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of Alport syndrome <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in <i>COL4A3</i>, <i>COL4A4</i>, or <i>COL4A5</i> identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. See <a class="figpopup" href="/books/NBK1207/table/alport.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figalportTmoleculargenetictestingused" rid-ob="figobalportTmoleculargenetictestingused">Table 1</a>.</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of Alport syndrome is broad, individuals with the distinctive findings described in <a href="#alport.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#alport.Option_1">Option 1</a>), whereas those with atypical features in whom the diagnosis of Alport syndrome has not been considered are more likely to be diagnosed using genomic testing (see <a href="#alport.Option_2">Option 2</a>).</p><div id="alport.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of Alport syndrome, the recommended <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approach is the use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>COL4A3</i>, <i>COL4A4</i>, <i>COL4A5</i>, and other genes of interest (see <a href="#alport.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For this disorder a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that also includes <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> is recommended (see <a class="figpopup" href="/books/NBK1207/table/alport.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figalportTmoleculargenetictestingused" rid-ob="figobalportTmoleculargenetictestingused">Table 1</a>).</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p>Note: Some laboratories may offer <a class="def" href="/books/n/gene/glossary/def-item/targeted-analysis-for-pathogenic-variants/">targeted analysis for pathogenic variants</a>, which may vary by laboratory. The pathogenic variants particularly common in the United States include the following:</p><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1207/table/alport.T.notable_col4a5_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figalportTnotablecol4a5pathogenicvaria" rid-ob="figobalportTnotablecol4a5pathogenicvaria">c.4692G&#x0003e;A</a> (p.Cys1564Ser)</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1207/table/alport.T.notable_col4a5_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figalportTnotablecol4a5pathogenicvaria" rid-ob="figobalportTnotablecol4a5pathogenicvaria">c.4946T&#x0003e;G</a> (p.Leu1649Arg)</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1207/table/alport.T.notable_col4a5_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figalportTnotablecol4a5pathogenicvaria" rid-ob="figobalportTnotablecol4a5pathogenicvaria">c.5030G&#x0003e;A</a> (p.Arg1677Gln)</div></li></ul></div><div id="alport.Option_2"><h4>Option 2</h4><p>When the diagnosis of Alport syndrome is not considered because an individual has atypical phenotypic features, <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible. <b>Exome array</b> (when clinically available) may be considered if <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic. For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><p>Note: Pathogenic variants in <i>COL4A3</i> and <i>COL4A4</i> can be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>) or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>). Pathogenic variants in <i>COL4A5</i> are <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> or heterozygous (<a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a>).</p><div id="alport.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Alport syndrome (AS)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1207/table/alport.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alport.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" colspan="2" scope="colgroup" headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of AS Attributed to Pathogenic Variants in This Gene&#x000a0;<sup>3</sup></th><th id="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>4</sup> Detectable by This Method</th></tr><tr><th headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_alport.T.molecular_genetic_testing_used_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup></th><th headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_alport.T.molecular_genetic_testing_used_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></th></tr></thead><tbody><tr><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL4A3</i></td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">12%-15%</td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Inheritance</b></td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3 hd_h_alport.T.molecular_genetic_testing_used_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">~98%&#x000a0;<sup>7</sup></td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3 hd_h_alport.T.molecular_genetic_testing_used_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">~2%&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">AR: ~45%<br />AD: ~55%</td></tr><tr><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL4A4</i></td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%-8%</td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR: ~45%<br />AD: 55%</td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3 hd_h_alport.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~98%&#x000a0;<sup>7</sup></td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3 hd_h_alport.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~2%&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL4A5</i></td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%-85%</td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL: 100%</td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3 hd_h_alport.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85%-90%&#x000a0;<sup>10,&#x000a0;11</sup></td><td headers="hd_h_alport.T.molecular_genetic_testing_used_1_1_1_3 hd_h_alport.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%-15%&#x000a0;<sup>12</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alport.TF.1.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="alport.TF.1.2"><p class="no_margin">See <a href="/books/NBK1207/#alport.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>3. </dt><dd><div id="alport.TF.1.3"><p class="no_margin"><a class="bk_pop" href="#alport.REF.fallerini.2014.252">Fallerini et al [2014]</a>, <a class="bk_pop" href="#alport.REF.morini_re.2014.2740">Morini&#x000e8;re et al [2014]</a>, <a class="bk_pop" href="#alport.REF.bullich.2018.363">Bullich et al [2018]</a></p></div></dd><dt>4. </dt><dd><div id="alport.TF.1.4"><p class="no_margin">See <a href="#alport.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>5. </dt><dd><div id="alport.TF.1.5"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>6. </dt><dd><div id="alport.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="alport.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#alport.REF.storey.2013.1945">Storey et al [2013]</a>, <a class="bk_pop" href="#alport.REF.fallerini.2014.252">Fallerini et al [2014]</a>, <a class="bk_pop" href="#alport.REF.morini_re.2014.2740">Morini&#x000e8;re et al [2014]</a></p></div></dd><dt>8. </dt><dd><div id="alport.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#alport.REF.morini_re.2014.2740">Morini&#x000e8;re et al [2014]</a>, <a class="bk_pop" href="#alport.REF.oka.2014.1535">Oka et al [2014]</a>, <a class="bk_pop" href="#alport.REF.mencarelli.2015.163">Mencarelli et al [2015]</a>, <a class="bk_pop" href="#alport.REF.bullich.2018.363">Bullich et al [2018]</a>, <a class="bk_pop" href="#alport.REF.daga.2018.302">Daga et al [2018]</a></p></div></dd><dt>9. </dt><dd><div id="alport.TF.1.9"><p class="no_margin"><a class="bk_pop" href="#alport.REF.gross.2003.1122">Gross et al [2003]</a>, <a class="bk_pop" href="#alport.REF.morini_re.2014.2740">Morini&#x000e8;re et al [2014]</a>, <a class="bk_pop" href="#alport.REF.oka.2014.1535">Oka et al [2014]</a>, <a class="bk_pop" href="#alport.REF.bullich.2018.363">Bullich et al [2018]</a></p></div></dd><dt>10. </dt><dd><div id="alport.TF.1.10"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>11. </dt><dd><div id="alport.TF.1.11"><p class="no_margin"><a class="bk_pop" href="#alport.REF.plant.1999.124">Plant et al [1999]</a>, <a class="bk_pop" href="#alport.REF.bekheirnia.2010.876">Bekheirnia et al [2010]</a>, <a class="bk_pop" href="#alport.REF.hanson.2011.198">Hanson et al [2011]</a>, <a class="bk_pop" href="#alport.REF.fallerini.2014.252">Fallerini et al [2014]</a>, <a class="bk_pop" href="#alport.REF.morini_re.2014.2740">Morini&#x000e8;re et al [2014]</a></p></div></dd><dt>12. </dt><dd><div id="alport.TF.1.12"><p class="no_margin"><a class="bk_pop" href="#alport.REF.renieri.1995.380">Renieri et al [1995]</a>, <a class="bk_pop" href="#alport.REF.plant.1999.124">Plant et al [1999]</a>, <a class="bk_pop" href="#alport.REF.jais.2003.2603">Jais et al [2003]</a>, <a class="bk_pop" href="#alport.REF.arrondel.2004.2030">Arrondel et al [2004]</a>, <a class="bk_pop" href="#alport.REF.king.2006.1061">King et al [2006]</a>, <a class="bk_pop" href="#alport.REF.bekheirnia.2010.876">Bekheirnia et al [2010]</a>, <a class="bk_pop" href="#alport.REF.hanson.2011.198">Hanson et al [2011]</a>, <a class="bk_pop" href="#alport.REF.morini_re.2014.2740">Morini&#x000e8;re et al [2014]</a>, <a class="bk_pop" href="#alport.REF.nozu.2017.733">Nozu et al [2017]</a></p></div></dd></dl></div></div></div><p><b>Digenic inheritance.</b>
<a class="bk_pop" href="#alport.REF.mencarelli.2015.163">Mencarelli et al [2015]</a> have described <a class="def" href="/books/n/gene/glossary/def-item/digenic/">digenic</a> inheritance of Alport syndrome in several families. The causative allelic variants may be <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> or <i>in trans</i>, and result in variable clinical features and transmission patterns.</p></div></div></div><div id="alport.Clinical_Characteristics"><h2 id="_alport_Clinical_Characteristics_">Clinical Characteristics</h2><div id="alport.Clinical_Description"><h3>Clinical Description</h3><p>In Alport syndrome a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hematuria with a nonprogressive or very slowly progressive course is observed.</p><p>Alport syndrome has renal and, frequently, cochlear and ocular manifestations. Approximately two thirds of Alport syndrome is <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> (XLAS); approximately 15% is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> (ARAS), and approximately 20% is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> (ADAS). In the X-linked form of Alport syndrome, disease manifestations are typically more severe in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. However, affected females with either XLAS or ARAS may have severe involvement as well. ADAS is typically a slowly progressive disorder; renal insufficiency and sensorineural hearing loss (SNHL) may not develop until relatively late in life.</p><div id="alport.Renal_Manifestations"><h4>Renal Manifestations</h4><p>The hallmark of Alport syndrome is microscopic hematuria (microhematuria). Males with XLAS have persistent microhematuria from early in life. Episodic gross hematuria can occur, especially during childhood. More than 90% of females with XLAS have microhematuria, although it may be intermittent. Individuals with ARAS have persistent microhematuria, with no gender difference. Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>COL4A3</i> or <i>COL4A4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> associated with ARAS have an estimated 50% incidence of persistent or intermittent microhematuria.</p><p>All males with XLAS develop proteinuria and, eventually, progressive renal insufficiency, which leads to end-stage renal disease (ESRD). Overall, an estimated 60% reach ESRD by age 30 years, and 90% by age 40 years [<a class="bk_pop" href="#alport.REF.jais.2000.649">Jais et al 2000</a>]. The rate of progression to ESRD is influenced by the nature of the <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (see <a href="#alport.GenotypePhenotype_Correlations__X">Genotype-Phenotype Correlations</a>).</p><p>Approximately 12% of females with XLAS develop ESRD before age 40 years, increasing to 30% by age 60 years and 40% by age 80 years [<a class="bk_pop" href="#alport.REF.jais.2003.2603">Jais et al 2003</a>].</p><p>Most individuals with ARAS develop significant proteinuria in late childhood or early adolescence and ESRD before age 30 years. Progression to ESRD occurs at a slower pace in individuals with ADAS (frequently delayed until later adulthood) than in those with XLAS or ARAS.</p></div><div id="alport.Renal_Biopsy"><h4>Renal Biopsy</h4><p><b>Immunohistochemical analysis</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Males with XLAS</b> typically show complete absence of immunostaining for the collagen &#x003b1;3(IV) chain, &#x003b1;4(IV) chain, and &#x003b1;5(IV) chain on renal biopsy.</div><div class="half_rhythm">Approximately 20% of males with XLAS show normal staining of renal basement membranes for the collagen &#x003b1;3(IV) chain, &#x003b1;4(IV) chain, and &#x003b1;5(IV) chain.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for XLAS</b> typically exhibit patchy loss of staining for the collagen &#x003b1;3, &#x003b1;4, and &#x003b1;5(IV) chains in GBMs and tubular basement membranes [<a class="bk_pop" href="#alport.REF.kashtan.1996.142">Kashtan et al 1996</a>]. Some heterozygous females exhibit normal staining for the collagen &#x003b1;3, &#x003b1;4, and &#x003b1;5(IV) chains in renal basement membranes.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Individuals with ARAS</b> show abnormalities of renal type IV collagen expression that differ from those of individuals with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disease. Individuals with ARAS typically exhibit complete absence of staining for the collagen &#x003b1;3(IV) chain and &#x003b1;4(IV) chain. However, whereas their GBMs show no staining for the collagen &#x003b1;5(IV) chain, staining of Bowman's capsules and tubular basement membranes for the collagen &#x003b1;5(IV) chain is positive [<a class="bk_pop" href="#alport.REF.gubler.1995.1142">Gubler et al 1995</a>]. Some individuals with ARAS exhibit normal renal basement membrane staining for the collagen &#x003b1;3(IV) chain, &#x003b1;4(IV) chain, and &#x003b1;5(IV) chain.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Individuals with ADAS</b> exhibit normal GBM staining for the collagen &#x003b1;3(IV) chain, &#x003b1;4(IV) chain, and &#x003b1;5(IV) chain.</div></li></ul><p><b>Electron microscopy</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Normal.</b> The normal glomerular capillary wall has a trilaminar appearance consisting of a homogeneous electron-dense layer (lamina densa) sandwiched between two electron-lucent layers (the laminae rara interna and externa).</div><div class="half_rhythm">The outer (subepithelial) aspect of the glomerular capillary wall, where it abuts the foot processes of the glomerular visceral epithelial cells, is smooth and regular.</div><div class="half_rhythm">A variety of techniques have been used to measure GBM width. The cutoff value in adults ranges from 250 nm to 330 nm, depending on technique. The cutoff value in children ranges from 200 nm to 250 nm, depending on technique (250 nm is within 2 SD of the mean at age 11 years).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Alport syndrome.</b> When diffusely present, the following three alterations are pathognomonic of Alport syndrome:</div><ul><li class="half_rhythm"><div>The lamina densa appears to be split into multiple interlacing strands of electron-dense material, resembling basket weaving.</div></li><li class="half_rhythm"><div>The lacunae between these strands are frequently occupied by round, electron-dense bodies (possibly entrapped cytoplasm).</div></li><li class="half_rhythm"><div>The glomerular capillary wall is diffusely thickened and its epithelial aspect is scalloped.</div></li></ul><div class="half_rhythm">However, the earliest change in Alport syndrome is diffuse thinning of the GBM. Children with XLAS and ARAS frequently exhibit only GBM thinning on renal biopsy. Women with XLAS and individuals with ADAS also may exhibit only GBM thinning. Marked variability in GBM width within a glomerulus in an individual with persistent microhematuria should raise suspicion of Alport syndrome.</div></li></ul></div><div id="alport.Skin_Biopsy"><h4>Skin Biopsy</h4><p>When renal biopsy is contraindicated (and genetic testing is not possible), a skin biopsy could be performed in place of the renal biopsy with the following findings:</p><ul><li class="half_rhythm"><div><b>Males with XLAS.</b> In about 80% of males, incubation of a skin biopsy specimen with a monoclonal antibody directed against the collagen &#x003b1;5(IV) chain shows complete absence of staining of epidermal basement membranes. Approximately 20% of males show normal staining.</div></li><li class="half_rhythm"><div><b>Females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for XLAS.</b> Approximately 60%-70% of heterozygous females exhibit discontinuous staining of the collagen &#x003b1;5(IV) chain [<a class="bk_pop" href="#alport.REF.van_der_loop.1999.1217">van der Loop et al 1999</a>]. This is attributed to <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>, by which it would be expected that one half of the basilar keratinocytes would express a normal collagen &#x003b1;5(IV) chain.</div></li><li class="half_rhythm"><div><b>Individuals with ARAS.</b> All individuals have normal skin reactivity for the collagen &#x003b1;5(IV) chain.</div></li><li class="half_rhythm"><div><b>Individuals with ADAS.</b> All individuals have normal skin reactivity for the collagen &#x003b1;5(IV) chain.</div></li></ul></div><div id="alport.Cochlear_Manifestations"><h4>Cochlear Manifestations</h4><p>Hearing loss in Alport syndrome is never <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>. Diminished hearing is frequently detectable by late childhood or early adolescence in boys with XLAS. In its early stages, the hearing deficit is detectable only by audiometry, with bilateral reduction in sensitivity to tones in the 2,000- to 8,000-Hz range. In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males, the hearing loss is progressive and eventually extends to other frequencies, including those of conversational speech. Hearing loss is frequently identifiable by formal assessment of hearing in late childhood, but in some families is not detectable until relatively late in life.</p><p>SNHL develops in 80%-90% of males with XLAS by age 40 years [<a class="bk_pop" href="#alport.REF.jais.2000.649">Jais et al 2000</a>]. The course of the hearing loss depends on the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (see <a href="#alport.GenotypePhenotype_Correlations__X">Genotype-Phenotype Correlations</a>). Hearing impairment in members of families with Alport syndrome is always accompanied by evidence of renal involvement; no convincing evidence that deaf males lacking renal disease can transmit Alport syndrome to their offspring has been reported. In females with XLAS, hearing loss is less frequent and tends to occur later in life.</p><p>There do not appear to be gender differences in the incidence or course of hearing loss in ARAS. Individuals with ARAS typically exhibit juvenile onset of hearing loss. Hearing loss may be a very late development in individuals with ADAS.</p><p>A histologic study of cochleas in individuals with Alport syndrome suggests that defective adhesion of the organ of Corti to the basilar membrane may underlie the hearing deficit [<a class="bk_pop" href="#alport.REF.merchant.2004.1609">Merchant et al 2004</a>].</p></div><div id="alport.Ocular_Manifestations"><h4>Ocular Manifestations</h4><p>Ocular lesions are common in Alport syndrome, occurring in 30%-40% of individuals with XLAS. The spectrum of ocular lesions appears to be similar in XLAS and ARAS. Ocular lesions appear to be relatively uncommon in ADAS.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Anterior lenticonus,</b> in which the central portion of the lens protrudes into the anterior chamber, is virtually pathognomonic in Alport syndrome. When present, anterior lenticonus is bilateral in approximately 75% of individuals. It is absent at birth, usually appearing during the second to third decade of life. Progressive distortion of the lens may occur, accompanied by increasing myopia. Lens opacities may be seen in conjunction with lenticonus, occasionally resulting from rupture of the anterior lens capsule.</div><div class="half_rhythm">All reported individuals with anterior lenticonus who have been adequately examined have exhibited evidence of chronic nephritis and sensorineural hearing loss. It is far more common in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males but can occur in females. The frequency of lenticonus in males with XLAS was 13% in one large series; its occurrence is related to the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (see <a href="#alport.GenotypePhenotype_Correlations__X">Genotype-Phenotype Correlations</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Maculopathy</b> consisting of whitish or yellowish flecks or granulations in the perimacular region was found in approximately 14% of males with XLAS in a large series. While the maculopathy is usually not associated with any visual abnormalities, some individuals have developed macular holes associated with severe thinning of the retina.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Corneal endothelial vesicles</b> (posterior polymorphous dystrophy) and <b>recurrent corneal erosion</b> may also be seen in individuals with Alport syndrome.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Bilateral posterior subcapsular cataracts</b> also occur frequently in individuals with Alport syndrome with diffuse leiomyomatosis (see <a href="#alport.Other">Other</a>).</div></li></ul></div><div id="alport.Other"><h4>Other</h4><p><b>Aneurysms of the thoracic and abdominal aorta</b> have been described in a small number of males with Alport syndrome [<a class="bk_pop" href="#alport.REF.lyons.2007.816">Lyons et al 2007</a>, <a class="bk_pop" href="#alport.REF.kashtan.2010.3554">Kashtan et al 2010</a>]. These aneurysms are notable for the relatively early age of diagnosis (age &#x0003c;40 years) and have required surgical intervention.</p><p><b>Diffuse leiomyomatosis.</b> The association of Alport syndrome with diffuse leiomyomatosis of the esophagus and tracheobronchial tree has been reported in several dozen families [<a class="bk_pop" href="#alport.REF.antignac.1996.172">Antignac &#x00026; Heidet 1996</a>, <a class="bk_pop" href="#alport.REF.mothes.2002.70">Mothes et al 2002</a>]. This results from large deletions that span the adjacent 5' ends of <i>COL4A5</i> and <i>COL4A6</i> [<a class="bk_pop" href="#alport.REF.zhou.1993.1167">Zhou et al 1993</a>] (see <a href="#alport.GenotypePhenotype_Correlations__X">Genotype-Phenotype Correlations</a>). Symptoms usually appear in late childhood and include dysphagia, postprandial vomiting, retrosternal or epigastric pain, recurrent bronchitis, dyspnea, cough, and stridor. Affected females in these kindreds typically exhibit genital leiomyomas as well, causing clitoral hypertrophy with variable involvement of the labia majora and uterus.</p></div></div><div id="alport.GenotypePhenotype_Correlations__X"><h3>Genotype-Phenotype Correlations &#x02013; XLAS</h3><p><b>Risk for end-stage renal disease (in untreated individuals)</b></p><ul><li class="half_rhythm"><div>Large rearrangements and pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> and frameshift variants confer a 90% probability of end-stage renal disease (ESRD) before age 30 years, with 50% reaching ESRD by age 20 years [<a class="bk_pop" href="#alport.REF.jais.2000.649">Jais et al 2000</a>].</div></li><li class="half_rhythm"><div>In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, the probability of ESRD before age 30 years is 70%, with 50% reaching ESRD by age 25 years.</div></li><li class="half_rhythm"><div>Missense variants are associated with only a 50% probability of ESRD before age 30 years and a renal half-life (the time it takes for 50% of the group to reach end stage; i.e., the need for dialysis or transplantation) of 32 years.</div></li><li class="half_rhythm"><div>In one study, <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that alter glycine and non-glycine residues in the 3' portion of <i>COL4A5</i> were associated with earlier development of ESRD, compared with missense variants that alter glycine residues in the 5' portion of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#alport.REF.gross.2002.1218">Gross et al 2002</a>]. In another study, pathogenic variants at the 5' end of <i>COL4A5</i> were associated with earlier ESRD, hearing loss, and ocular changes [<a class="bk_pop" href="#alport.REF.bekheirnia.2010.876">Bekheirnia et al 2010</a>].</div></li></ul><p><b>Risk for deafness</b></p><ul><li class="half_rhythm"><div>In individuals with large rearrangements of <i>COL4A5</i> or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, or <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, the risk for deafness is 50% at age ten years.</div></li><li class="half_rhythm"><div>In individuals with <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, the risk for deafness does not reach 50% until age 20 years.</div></li></ul><p><b>Risk for anterior lenticonus.</b> Anterior lenticonus occurs in approximately 15% of males with XLAS. Anterior lenticonus is almost entirely restricted to families with Alport syndrome with hearing loss and progression to ESRD before age 30 years. This observation is explained by the finding that lenticonus is significantly more common in individuals with a <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or a small <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in a premature stop codon than in those with pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants [<a class="bk_pop" href="#alport.REF.jais.2000.649">Jais et al 2000</a>].</p><p><b>Risk for diffuse leiomyomatosis</b></p><ul><li class="half_rhythm"><div>All families in which XLAS cosegregates with diffuse leiomyomatosis exhibit large deletions that span the adjacent 5' ends of <i>COL4A5</i> and <i>COL4A6</i>. These deletions involve varying lengths of <i>COL4A5</i>, but the <i>COL4A6</i> breakpoint is always located in the second <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#alport.REF.antignac.1996.172">Antignac &#x00026; Heidet 1996</a>].</div></li><li class="half_rhythm"><div>Leiomyomatosis does not occur in individuals with deletions of <i>COL4A5</i> and <i>COL4A6</i> that extend beyond <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 2 of <i>COL4A6</i>.</div></li><li class="half_rhythm"><div>Pathogenic variants of <i>COL4A6</i> alone do not appear to cause Alport syndrome, a finding consistent with the absence of the &#x003b1;6(IV) chain from normal GBM.</div></li></ul></div><div id="alport.Penetrance"><h3>Penetrance</h3><p>Penetrance may be decreased in ADAS; at present, data are insufficient to draw a definitive conclusion.</p></div><div id="alport.Nomenclature"><h3>Nomenclature</h3><p>The term "benign <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hematuria," previously applied to Alport syndrome, is a misnomer that should no longer be used.</p></div><div id="alport.Prevalence"><h3>Prevalence</h3><p>The prevalence of Alport syndrome has been estimated at 1:50,000 live births [<a class="bk_pop" href="#alport.REF.levy.2000.925">Levy &#x00026; Feingold 2000</a>]. Data from several series suggest that approximately one fifth of children evaluated by pediatric nephrologists for <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> microhematuria receive a diagnosis of Alport syndrome. According to the United States Renal Data System (<a href="https://www.usrds.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">USRDS</a>), approximately 0.2% of adults and 3% of children in the United States with ESRD carry a diagnosis of Alport syndrome.</p></div></div><div id="alport.Genetically_Related_Allelic_Disor"><h2 id="_alport_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p><b>AMME complex</b> (<i>A</i>lport syndrome, intellectual disability [<i>m</i>ental retardation], <i>m</i>idface hypoplasia, and <i>e</i>lliptocytosis; OMIM <a href="https://omim.org/entry/300194" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300194</a>) was described in two brothers shown to have a microdeletion of Xq22.3 involving all of <i>COL4A5</i> and extending beyond its 3' end.</p><p><b>Focal segmental glomerulosclerosis.</b> Pathogenic variants in <i>COL4A3</i>, <i>COL4A4</i>, or <i>COLA5</i> are not unusual in adult patients with proteinuria and renal biopsy findings of focal segmental glomerulosclerosis [<a class="bk_pop" href="#alport.REF.gast.2016.961">Gast et al 2016</a>].</p></div><div id="alport.Differential_Diagnosis"><h2 id="_alport_Differential_Diagnosis_">Differential Diagnosis</h2><div id="alport.Conditions_with_Hematuria"><h3>Conditions with Hematuria</h3><p>Alport syndrome most often presents in childhood, and thus must be differentiated from other causes of persistent (&#x0003e;6 months in duration) microhematuria in children.</p><ul><li class="half_rhythm"><div class="half_rhythm">The first step in the evaluation of hematuria in children is to attempt to establish the source of the hematuria (renal/glomerular, renal/post-glomerular, post-renal).</div><ul><li class="half_rhythm"><div>This often involves evaluation of urinary erythrocyte morphology by phase contrast microscopy, urinary calcium measurement, and/or renal ultrasound examination.</div></li><li class="half_rhythm"><div>Family history is an important component of the initial evaluation of the child with hematuria. When possible, obtaining urinalyses on first-degree relatives can also be informative.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Once microhematuria is provisionally localized to the glomeruli, possible etiologies include a number of chronic glomerulopathies.</div><div class="half_rhythm">In the child with no known family history of hematuria, the most likely diagnoses are IgA nephropathy, Alport syndrome, and <a href="/books/n/gene/mpgn/">C3 glomerulopathy</a>).</div></li></ul></div><div id="alport.Combined_Nephritis_and_Deafness"><h3>Combined Nephritis and Deafness</h3><p><a href="/books/n/gene/myh9/"><b><i>MYH9</i>-related disorders</b></a><b>.</b>
<i>MYH9</i>-related disorders (MYH9RD) are characterized by large platelets and thrombocytopenia, both of which are present from birth. MYH9RD is variably associated with young-adult onset of progressive sensorineural hearing loss, presenile cataract, elevation of liver enzymes, and renal disease manifesting initially as glomerular nephropathy. Before identification of pathogenic variants in <i>MYH9</i>, individuals with MYH9RD were diagnosed as having Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly, or Sebastian syndrome based on the combination of different clinical findings at the time of diagnosis. Some individuals with MYH9RD exhibit ultrastructural changes of the glomerular capillary wall reminiscent of those seen in individuals with Alport syndrome. MYH9RD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div></div><div id="alport.Management"><h2 id="_alport_Management_">Management</h2><div id="alport.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Alport syndrome, the evaluations summarized in <a class="figpopup" href="/books/NBK1207/table/alport.T.recommended_evaluations_followi/?report=objectonly" target="object" rid-figpopup="figalportTrecommendedevaluationsfollowi" rid-ob="figobalportTrecommendedevaluationsfollowi">Table 2</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="alport.T.recommended_evaluations_followi" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with Alport Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1207/table/alport.T.recommended_evaluations_followi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alport.T.recommended_evaluations_followi_lrgtbl__"><table><thead><tr><th id="hd_h_alport.T.recommended_evaluations_followi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/<br />Concern</th><th id="hd_h_alport.T.recommended_evaluations_followi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_alport.T.recommended_evaluations_followi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Renal</b></td><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline testing of urine protein excretion</td><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Overt proteinuria (urine protein-creatinine ratio &#x0003e;0.2 or, in a child, 24-hr urine protein &#x0003e;4 mg/m<sup>2</sup>/hr) is an important indicator of renal disease progression in individuals w/Alport syndrome.</td></tr><tr><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hearing</b></td><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline audiogram</td><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High-frequency sensorineural deafness typically becomes detectable by audiogram in late childhood.</td></tr><tr><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Vision</b></td><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline ophthalmologic evaluation</td><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluate for maculopathy &#x00026; anterior lenticonus, which are typically asymptomatic.</td></tr><tr><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_alport.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div></div></div><div id="alport.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Clinical practice recommendations for the treatment of individuals with Alport syndrome have been published [<a class="bk_pop" href="#alport.REF.kashtan.2013.5">Kashtan et al 2013</a>]. These recommendations encourage early detection of microalbuminuria and proteinuria through regular surveillance and early intervention aimed at suppressing proteinuria using angiotensin antagonists (click <a href="/pmc/articles/PMC3505543/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a> for full text).</p><div id="alport.T.treatment_of_manifestations_in" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Alport Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1207/table/alport.T.treatment_of_manifestations_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alport.T.treatment_of_manifestations_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Renal disease</b></td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker</td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early treatment delays onset of ESRD.&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Standard management for hypertension</td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Renal transplantation for ESRD</td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Special considerations apply to selection of potential living related kidney donors for individuals w/XLAS (see <b>Note on selection of kidney donors</b>).</td></tr><tr><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hearing deficit</b></td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing aids as needed</td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Vision issues</b></td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cataract removal</td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Diffuse</b><br /><b>leiomyomatosis</b></td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Symptomatic leiomyomas may require surgical intervention.</td><td headers="hd_h_alport.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alport.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#alport.REF.gross.2012.494">Gross et al [2012]</a></p></div></dd></dl></div></div></div><p><b>Note on selection of kidney donors.</b> The following discussion considers potential donors on the basis of gender and the presence or absence of hematuria:</p><ul><li class="half_rhythm"><div><b>Male relative without hematuria.</b> The optimal living related donor is a male who has a normal urinalysis and is therefore unaffected.</div></li><li class="half_rhythm"><div><b>Male relative with hematuria.</b> A related male with hematuria probably has Alport syndrome and cannot be a kidney donor.</div></li><li class="half_rhythm"><div><b>Female relative without hematuria.</b> Female relatives who have normal urinalyses are probably unaffected, although approximately 5% of females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are asymptomatic. It is rare for asymptomatic females whose children are also asymptomatic to be heterozygous. Asymptomatic females can probably donate a kidney safely but should be informed of their risk of having <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male children to whom they will not be able to donate a kidney. Genetic status can be confirmed or excluded by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the pathogenic variant in the family is known.</div></li><li class="half_rhythm"><div><b>Female relative with hematuria (i.e., <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female).</b> Females heterozygous for a <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should only be considered as potential kidney donors if no asymptomatic living donors are available.</div><ul><li class="half_rhythm"><div>The presence of proteinuria or sensorineural deafness is an absolute contraindication to kidney donation as these are risk factors for progression to ESRD.</div></li><li class="half_rhythm"><div>Heterozygous females younger than age 40 years should not be used as donors, even in the absence of proteinuria or deafness.</div></li><li class="half_rhythm"><div>Heterozygous females age 40 years or older who have normal renal function, blood pressure, and hearing and no proteinuria can be considered as donors because the risk of late progression to ESRD appears to be low in such individuals. However, the donor should be informed of the risk (albeit low) of late progression to ESRD.</div></li></ul></li></ul></div><div id="alport.Surveillance"><h3>Surveillance</h3><p>Clinical practice recommendations for the treatment and health surveillance of individuals with Alport syndrome have been published [<a class="bk_pop" href="#alport.REF.kashtan.2013.5">Kashtan et al 2013</a>].</p><div id="alport.T.recommended_surveillance_for_in" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with Alport Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1207/table/alport.T.recommended_surveillance_for_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alport.T.recommended_surveillance_for_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/<br />Concern</th><th id="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Renal</b></td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Regular follow up by nephrologist to include urinalysis, renal function assessment, &#x00026; blood pressure determination&#x000a0;<sup>1</sup></td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Annually if urine microalbumin-creatinine ratio &#x0003c;30 mg/g or urine protein-creatinine ratio &#x0003c;0.2 mg/mg</div></li><li class="half_rhythm"><div>Every 6 mos if urine microalbumin-creatinine ratio &#x0003e;30 mg/g or urine protein-creatinine ratio &#x0003e;0.2 mg/mg</div></li></ul>
</td></tr><tr><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">For at-risk transplant recipients&#x000a0;<sup>2</sup>: monitor for development of anti-glomerular basement membrane antibody-mediated glomerulonephritis.</td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monthly for 1st 12 mos post transplant</td></tr><tr><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hearing</b></td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Audiologic evaluation starting at age 6-7 yrs</td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 1-2 years</td></tr><tr><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Vision</b></td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor for maculopathy, anterior lenticonus, corneal erosions, &#x00026; cataracts.</td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Starting in adolescence in males w/a truncating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of <i>COL4A5</i> &#x00026; in individuals w/ARAS; repeat every 1-2 yrs.</td></tr><tr><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiac</b></td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiac evaluation for aortic dilation (for males w/XLAS) as part of transplant preparation</td><td headers="hd_h_alport.T.recommended_surveillance_for_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Echocardiogram follow-up interval as determined by findings &#x00026; directed by cardiologist</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alport.TF.4.1"><p class="no_margin">Although most females with XLAS exhibit only asymptomatic microhematuria, there can be a significant risk for progression to ESRD [<a class="bk_pop" href="#alport.REF.jais.2003.2603">Jais et al 2003</a>]. For this reason, all women with a diagnosis of Alport syndrome need to be monitored regularly for the development of proteinuria and hypertension.</p></div></dd><dt>2. </dt><dd><div id="alport.TF.4.2"><p class="no_margin">Males with XLAS and a truncating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>COL4A5</i> and individuals with ARAS</p></div></dd></dl></div></div></div></div><div id="alport.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Individuals who suffer recurrent corneal erosions may need to take measures (e.g., wearing goggles when riding a bicycle) to protect their corneas from minor trauma.</p><p>Exposure to loud noise should be minimized.</p></div><div id="alport.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate family members at risk for Alport syndrome in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures. Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known. Molecular genetic testing is necessary to exclude heterozygosity in an at-risk individual who does not have hematuria.</div></li><li class="half_rhythm"><div>Urinalysis and blood pressure determination:</div><ul><li class="half_rhythm"><div>In males, a single urinalysis is sufficient.</div></li><li class="half_rhythm"><div>In females, several urinalyses should be performed before concluding that hematuria is absent.</div></li></ul></li></ul><p>Relatives found to have proteinuria, hypertension, and/or a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should be referred to a nephrologist for further evaluation. In the absence of proteinuria or hypertension, relatives at risk should, at a minimum, have an annual urinalysis and measurement of blood pressure if <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is not available.</p><p>See <a href="#alport.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="alport.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Women with Alport syndrome are at risk for pregnancy complications including increased proteinuria, renal insufficiency, worsened hypertension, and preeclampsia. The risks of these complications are higher in women with preexisting renal insufficiency, proteinuria, or hypertension. Optimal maternal and fetal outcomes may require the involvement of a nephrologist as well as high-risk obstetrics.</p></div><div id="alport.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="alport.Genetic_Counseling"><h2 id="_alport_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="alport.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Alport syndrome caused by pathogenic variants in <i>COL4A5</i> is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner (XLAS).</p><p>Alport syndrome caused by pathogenic variants in <i>COL4A3</i> or <i>COL4A4</i> can be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> (ARAS) or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner (ADAS).</p></div><div id="alport.XLinked_Inheritance"><h3>X-Linked Inheritance</h3><div id="alport.Risk_to_Family_Members"><h4>Risk to Family Members</h4><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of a male with XLAS will not have the disease nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a>. Note: If a woman has more than one affected child and no other affected relatives and if the <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the likelihood that that individual's mother is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> is 85%-90%. Alternatively, the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not heterozygous; approximately 10%-15% of male probands have XLAS as the result of a <i>de novo</i> pathogenic variant.</div></li><li class="half_rhythm"><div>Recommended evaluations for the mother of a male known to have XLAS include the following:</div><ul><li class="half_rhythm"><div><b>Urinalysis.</b> The presence of microhematuria indicates that she is likely to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. If proteinuria or hypertension is present, she should be referred to a nephrologist for further evaluation.</div></li><li class="half_rhythm"><div><b>Molecular genetic testing</b> is necessary to exclude the <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> state in an at-risk female who does not have hematuria or hypertension. (Note: Molecular genetic testing requires prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.)</div></li></ul></li><li class="half_rhythm"><div>If the mother of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not found to have proteinuria or hypertension and if <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is not possible, she should have, at a minimum, an annual urinalysis and measurement of blood pressure.</div></li></ul><p><b>Parents of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father or the mother of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have the <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, or the proband may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant.</div></li><li class="half_rhythm"><div>Evaluation of parents of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with XLAS begins with urinalysis and proceeds (for both parents) as described for the mother of a male proband.</div></li></ul><p><b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of a male proband depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant may or may not be symptomatic.</div></li><li class="half_rhythm"><div>If the mother is not <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is slightly greater than that of the general population (though still &#x0003c;1%) because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#alport.REF.beicht.2013.474">Beicht et al 2013</a>, <a class="bk_pop" href="#alport.REF.okamoto.2019.155">Okamoto et al 2019</a>].</div></li></ul><p><b>Sibs of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of a female proband depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant may or may not be symptomatic.</div></li><li class="half_rhythm"><div>If the father of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, he will transmit it to all of his daughters and none of his sons.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population (though still &#x0003c;1%) because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Affected males transmit the <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to all of their daughters (who may or may not be symptomatic) and none of their sons.</div></li><li class="half_rhythm"><div>Heterozygous females have a 50% chance of transmitting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to each child: sons who inherit the <i>COL4A5</i> pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; daughters will have a range of possible phenotypic expression.</div></li></ul><p><b>Other family members.</b> The male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and the aunts' offspring, depending on their gender, may be at risk of being heterozygous for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p></div><div id="alport.Heterozygote_Detection"><h4>Heterozygote Detection</h4><p>Molecular genetic testing for at-risk females who lack microhematuria requires prior identification of the <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p>Note: (1) Females are heterozygotes for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder and may develop clinical findings related to the disorder. (2) Identification of female heterozygotes requires either (a) prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and then, if a pathogenic variant is not identified, by methods to detect gross structural abnormalities.</p></div></div><div id="alport.Autosomal_Recessive_Inheritance"><h3>Autosomal Recessive Inheritance</h3><div id="alport.Risk_to_Family_Members_1"><h4>Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>COL4A3</i> or <i>COL4A4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Approximately 50% of heterozygotes exhibit persistent or intermittent microhematuria.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>, and a 25% chance of being unaffected and not a heterozygote.</div></li><li class="half_rhythm"><div>Approximately 50% of heterozygotes exhibit persistent or intermittent microhematuria.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with ARAS are obligate heterozygotes for a <i>COL4A3</i> or <i>COL4A4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>COL4A3</i> or <i>COL4A4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="alport.Heterozygote_Detection_1"><h4>Heterozygote Detection</h4><p>Genetic testing of at-risk relatives is possible if the <i>COL4A3</i> or <i>COL4A4</i> pathogenic variants have been identified in the family.</p></div></div><div id="alport.Autosomal_Dominant_Inheritance__R"><h3>Autosomal Dominant Inheritance &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with ADAS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with ADAS may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>COL4A3</i> or <i>COL4A4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <i>de novo</i> pathogenic variants is unknown.</div></li><li class="half_rhythm"><div>Urinalysis is recommended for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the pathogenic variant has been identified in the proband.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</div></li><li class="half_rhythm"><div>Note: Although most individuals diagnosed with ADAS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of a proband depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to have the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, the risk to sibs is 50%.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <i>COL4A3</i> or <i>COL4A4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#alport.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li><li class="half_rhythm"><div>If the parents have not been tested for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> but are clinically unaffected, the risk to the sibs of a proband appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for ADAS because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Offspring of an individual with ADAS are at a 50% risk of inheriting the <i>COL4A3</i> or <i>COL4A4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <i>COL4A3</i> or <i>COL4A4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at risk.</p></div><div id="alport.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#alport.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Screening of potential living related kidney donors.</b> Most individuals with Alport syndrome who require kidney transplantation have <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disease. Both <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females with XLAS are at risk for ESRD. Potential living related donors must be evaluated carefully to avoid nephrectomy in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual. <a class="bk_pop" href="#alport.REF.kashtan.2006.651">Kashtan [2006]</a> discusses in detail the evaluation of potential donors.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div><b><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></b> or <b><a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance.</b> It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, or are at risk of being heterozygous.</div></li><li class="half_rhythm"><div><b>Autosomal dominant inheritance.</b> It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="alport.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>COL4A3</i>, <i>COL4A4</i>, or <i>COL4A5</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk for Alport syndrome and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and in families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="alport.Resources"><h2 id="_alport_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Alport Syndrome Foundation</b></div><div>1608 East Briarwood Terrace</div><div>Phoenix AZ 85048-9414</div><div><b>Phone:</b> 480-460-0621</div><div><b>Fax:</b> 480-460-0621</div><div><b>Email:</b> info@alportsyndrome.org</div><div><a href="http://www.alportsyndrome.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alportsyndrome.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Alport%20syndrome&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alport syndrome</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=alportsyndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alport syndrome</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22265/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alport syndrome</a></div></li><li class="half_rhythm"><div><b>Kidney Foundation of Canada</b></div><div>310-5160 Decarie Blvd.</div><div>Montreal Ontario H3X 2H9 </div><div>Canada</div><div><b>Phone:</b> 800-361-7494 (toll-free); 514-369-4806</div><div><b>Fax:</b> 514-369-2472 </div><div><b>Email:</b> info@kidney.ca</div><div><a href="http://www.kidney.on.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kidney.ca</a></div></li><li class="half_rhythm"><div><b>National Association of the Deaf (NAD)</b></div><div>8630 Fenton Street</div><div>Suite 820</div><div>Silver Spring MD 20910</div><div><b>Phone:</b> 301-587-1788; 301-587-1789 (TTY)</div><div><b>Fax:</b> 301-587-1791</div><div><b>Email:</b> nad.info@nad.org</div><div><a href="http://www.nad.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nad.org</a></div></li><li class="half_rhythm"><div><b>National Kidney Foundation (NKF)</b></div><div>30 East 33rd Street</div><div>New York NY 10016</div><div><b>Phone:</b> 800-622-9010 (toll-free); 212-889-2210</div><div><b>Email:</b> info@kidney.org</div><div><a href="http://www.kidney.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kidney.org</a></div></li><li class="half_rhythm"><div><b>Alport Syndrome Treatments and Outcomes Registry (ASTOR)</b></div><div>University of Minnesota, Department of Pediatrics</div><div>516 Delaware Street Southeast</div><div>13-148 PWB</div><div>Minneapolis MN 55455</div><div><b>Phone:</b> 800-688-5252 #67632 (toll-free); 612-626-7632</div><div><b>Fax:</b> 612-626-1165</div><div><b>Email:</b> cassi044@umn.edu</div><div><a href="http://www.alportregistry.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alportregistry.org</a></div></li></ul></div><div id="alport.Molecular_Genetics"><h2 id="_alport_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="alport.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Alport Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1207/table/alport.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alport.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_alport.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_alport.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_alport.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_alport.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_alport.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_alport.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_alport.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1285" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>COL4A3</i></a></td><td headers="hd_b_alport.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1285" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q36<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q01955" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collagen alpha-3(IV) chain</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/COL4A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A3 gene homepage - Collagen, type IV, alpha 3</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL4A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A3</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=COL4A3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A3</a></td></tr><tr><td headers="hd_b_alport.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1286" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>COL4A4</i></a></td><td headers="hd_b_alport.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1286" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q36<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P53420" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collagen alpha-4(IV) chain</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/COL4A4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A4 homepage - Collagen, type IV, alpha 4</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL4A4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A4</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=COL4A4[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A4</a></td></tr><tr><td headers="hd_b_alport.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1287" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>COL4A5</i></a></td><td headers="hd_b_alport.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1287" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq22<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P29400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collagen alpha-5(IV) chain</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://arup.utah.edu/database/ALPORT/ALPORT_welcome.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">The Alport syndrome COL4A5 variant database</a><br /><a href="https://databases.lovd.nl/shared/genes/COL4A5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A5 homepage - Collagen, type IV, alpha 5</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL4A5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A5</a></td><td headers="hd_b_alport.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=COL4A5[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL4A5</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="alport.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="alport.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Alport Syndrome (<a href="/omim/104200,120070,120131,203780,301050,303630" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1207/table/alport.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alport.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/104200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">104200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALPORT SYNDROME 3, AUTOSOMAL DOMINANT; ATS3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120070" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120070</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLLAGEN, TYPE IV, ALPHA-3; COL4A3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120131" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120131</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLLAGEN, TYPE IV, ALPHA-4; COL4A4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/203780" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">203780</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALPORT SYNDROME 2, AUTOSOMAL RECESSIVE; ATS2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/301050" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">301050</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALPORT SYNDROME 1, X-LINKED; ATS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/303630" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">303630</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLLAGEN, TYPE IV, ALPHA-5; COL4A5</td></tr></tbody></table></div></div><div id="alport.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><b>Basement membranes.</b> Basement membranes, the sheet-like structures that support epithelial and endothelial cells, are composed of several major and minor glycoproteins. Collagen IV is present ubiquitously in basement membranes, where it is the major collagenous component. Collagen IV molecules secreted by endothelial and epithelial cells self-associate into polygonal networks, which interact with laminin networks, as well as with nidogens, proteoglycans, and other glycoproteins, to form basement membranes.</p><p><b>Collagen IV.</b> Collagen IV &#x003b1; chains share basic structural features and show extensive sequence homology. The major structural features of &#x003b1;(IV) chains are the following:</p><ul><li class="half_rhythm"><div>A (Gly)-X-Y collagenous <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of approximately 1,400 residues</div></li><li class="half_rhythm"><div>A carboxy-terminal non-collagenous (NC1) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of approximately 230 residues and 12 conserved cysteine residues, which participate in intrachain and interchain disulfide bonds</div></li><li class="half_rhythm"><div>A non-collagenous amino terminal sequence of 15-20 residues</div></li></ul><p>Approximately 20 interruptions of the collagenous triplet sequence are present in the collagenous <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>.</p><p>Collagen IV chains form helical heterotrimers through associations between their COO- NC1 domains. The heterotrimers form networks through intermolecular interaction such as:</p><ul><li class="half_rhythm"><div>End-to-end linkages between the COO- NC1 domains of two heterotrimers;</div></li><li class="half_rhythm"><div>Covalent interactions between four heterotrimers at their NH- ends; and</div></li><li class="half_rhythm"><div>Lateral associations between heterotrimers via binding of the COO- domains to sites along the collagenous region of another heterotrimer.</div></li></ul><p>Linkages between collagen IV molecules form a scaffolding for the deposition of other matrix glycoproteins and for cell attachment.</p><p>In the normal developing kidney:</p><ul><li class="half_rhythm"><div>Collagen &#x003b1;1(IV) and collagen &#x003b1;2(IV) chains predominate in the primordial glomerular basement membrane (GBM) of immature glomeruli.</div></li><li class="half_rhythm"><div>The formation of capillary loops within the maturing glomeruli is associated with the appearance of collagen &#x003b1;3, &#x003b1;4, and &#x003b1;5(IV) chains in the GBM.</div></li><li class="half_rhythm"><div>As glomerular maturation progresses, the &#x003b1;3, &#x003b1;4, and &#x003b1;5(IV) chains become the predominant collagen IV chains in GBM.</div></li></ul><p><b>Mechanism of disease causation.</b> Absence or underexpression of the collagen &#x003b1;3, &#x003b1;4, &#x003b1;5, and possibly &#x003b1;6(IV) chains in the basement membrane such that the networks that they form are absent &#x02013; or, if present, are defective &#x02013; cause the clinical features of Alport syndrome.</p><p>A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> affecting one of the chains involved in the collagen IV &#x003b1;345 network can prevent basement membrane expression not only of that chain but of the other two chains as well. Similarly, a pathogenic variant involving the &#x003b1;5(IV) chain can interfere with basement membrane expression of the &#x003b1;6 chain.</p><p>Most <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> collagen IV variants occur in glycine-encoding codons. The presence of a bulkier amino acid in a glycine position presumably creates a kink or an unfolding in the triple helix, as is observed in collagen &#x003b1;1(I) (see <a href="/books/n/gene/oi/"><i>COL1A1/2</i>-Related Osteogenesis Imperfecta</a> and other genetic disorders of collagen). Abnormally folded collagen triple helices exhibit increased susceptibility to proteolytic degradation. The position of the substituted glycine, or the substituting amino acid itself, may influence protein folding and ultimately the severity of the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p><b><i>COL4A3-</i> and <i>COL4A4</i>-specific laboratory technical considerations.</b> Variants in <i>COL4A3</i> and <i>COL4A4</i> can be associated with either AR or AD disease. There is no specific association between the type of variant (e.g., <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>) and inheritance pattern.</p><div id="alport.T.notable_col4a5_pathogenic_varia" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Notable <i>COL4A5</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1207/table/alport.T.notable_col4a5_pathogenic_varia/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alport.T.notable_col4a5_pathogenic_varia_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000495.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000495<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000486.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000486<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4692G&#x0003e;A</td><td headers="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys1564Ser</td><td headers="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_4" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Common in the United States</td></tr><tr><td headers="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4946T&#x0003e;G</td><td headers="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu1649Arg</td></tr><tr><td headers="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.5030G&#x0003e;A</td><td headers="hd_h_alport.T.notable_col4a5_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1677Gln</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div></div></div><div id="alport.References"><h2 id="_alport_References_">References</h2><div id="alport.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="alport.REF.antignac.1996.172">Antignac C, Heidet L. Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis. <span><span class="ref-journal">Contrib Nephrol. </span>1996;<span class="ref-vol">117</span>:172–82.</span> [<a href="/pubmed/8801045" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8801045</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.arrondel.2004.2030">Arrondel C, Desch&#x000ea;nes G, Le Meur Y, Viau A, Cordonnier C, Fournier A, Amadeo S, Gubler MC, Antignac C, Heidet L. A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia. <span><span class="ref-journal">Kidney Int. </span>2004;<span class="ref-vol">65</span>:2030–40.</span> [<a href="/pubmed/15149316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15149316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.beicht.2013.474">Beicht S, Strobl-Wildemann G, Rath S, Wachter O, Alberer M, Kaminsky E, Weber LT, Hinrichsen T, Klein HG, Hoefele J. Next generation sequencing as a useful tool in the diagnostics of mosaicism in Alport syndrome. <span><span class="ref-journal">Gene. </span>2013;<span class="ref-vol">526</span>:474–7.</span> [<a href="/pubmed/23732293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23732293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.bekheirnia.2010.876">Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW. Genotype-phenotype correlation in X-linked Alport syndrome. <span><span class="ref-journal">J Am Soc Nephrol. </span>2010;<span class="ref-vol">21</span>:876–83.</span> [<a href="/pmc/articles/PMC2865738/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2865738</span></a>] [<a href="/pubmed/20378821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20378821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.bullich.2018.363">Bullich G, Domingo-Gallego A, Vargas I, Ruiz P, Lorente-Grandoso L, Furlano M, Fraga G, Madrid &#x000c1;, Ariceta G, Borreg&#x000e1;n M, Pi&#x000f1;ero-Fern&#x000e1;ndez JA, Rodr&#x000ed;guez-Pe&#x000f1;a L, Ballesta-Mart&#x000ed;nez MJ, Llano-Rivas I, Me&#x000f1;ica MA, Ballar&#x000ed;n J, Torrents D, Torra R, Ars E. A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases. <span><span class="ref-journal">Kidney Int. </span>2018;<span class="ref-vol">94</span>:363–71.</span> [<a href="/pubmed/29801666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29801666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.daga.2018.302">Daga S, Baldassarri M, Lo Rizzo C, Fallerini C, Imperatore V, Longo I, Frullanti E, Landucci E, Massella L, Pecoraro C, Garosi G, Ariani F, Mencarelli MA, Mari F, Renieri A, Pinto AM. Urine-derived podocytes-lineage cells: a promising tool for precision medicine in Alport syndrome. <span><span class="ref-journal">Hum Mutat. </span>2018;<span class="ref-vol">39</span>:302–14.</span> [<a href="/pubmed/29098738" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29098738</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.fallerini.2014.252">Fallerini C, Dosa L, Tita R, Del Prete D, Feriozzi S, Gai G, Clementi M, La Manna A, Miglietti N, Mancini R, Mandrile G, Ghiggeri GM, Piaggio G, Brancati F, Diano L, Frate E, Pinciaroli AR, Giani M, Castorina P, Bresin E, Giachino D, De Marchi M, Mari F, Bruttini M, Renieri A, Ariani F. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. <span><span class="ref-journal">Clin Genet. </span>2014;<span class="ref-vol">86</span>:252–7.</span> [<a href="/pubmed/24033287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24033287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.gast.2016.961">Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, Venkat-Raman G, Ennis S. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2016;<span class="ref-vol">31</span>:961–70.</span> [<a href="/pubmed/26346198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26346198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.gross.2012.494">Gross O, Licht C, Anders HJ, Hoppe B, Beck B, T&#x000f6;nshoff B, H&#x000f6;cker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, D&#x000f6;tsch J, M&#x000fc;ller-Wiefel DE, Hoyer P, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, M&#x000fc;ller GA, Weber M, et al.  Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. <span><span class="ref-journal">Kidney Int. </span>2012;<span class="ref-vol">81</span>:494–501.</span> [<a href="/pubmed/22166847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22166847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.gross.2002.1218">Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2002;<span class="ref-vol">17</span>:1218–27.</span> [<a href="/pubmed/12105244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12105244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.gross.2003.1122">Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2003;<span class="ref-vol">18</span>:1122–7.</span> [<a href="/pubmed/12748344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12748344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.gubler.1995.1142">Gubler MC, Knebelmann B, Beziau A, Broyer M, Pirson Y, Haddoum F, Kleppel MM, Antignac C. Autosomal recessive Alport syndrome: immunohistochemical study of type IV collagen chain distribution. <span><span class="ref-journal">Kidney Int. </span>1995;<span class="ref-vol">47</span>:1142–7.</span> [<a href="/pubmed/7783412" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7783412</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.hanson.2011.198">Hanson H, Storey H, Pagan J, Flinter F. The value of clinical criteria in identifying patients with X-linked Alport syndrome. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2011;<span class="ref-vol">6</span>:198–203.</span> [<a href="/pmc/articles/PMC3022243/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3022243</span></a>] [<a href="/pubmed/20884774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20884774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.jais.2003.2603">Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Dahan K, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. <span><span class="ref-journal">J Am Soc Nephrol. </span>2003;<span class="ref-vol">14</span>:2603–10.</span> [<a href="/pubmed/14514738" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14514738</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.jais.2000.649">Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. <span><span class="ref-journal">J Am Soc Nephrol. </span>2000;<span class="ref-vol">11</span>:649–57.</span> [<a href="/pubmed/10752524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10752524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.kashtan.2004.1290">Kashtan CE. Diagnosis of Alport syndrome. <span><span class="ref-journal">Kidney Int. </span>2004;<span class="ref-vol">66</span>:1290–1.</span> [<a href="/pubmed/15327435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15327435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.kashtan.2006.651">Kashtan CE. Renal transplantation in patients with Alport syndrome. <span><span class="ref-journal">Pediatr Transplant. </span>2006;<span class="ref-vol">10</span>:651–7.</span> [<a href="/pubmed/16911486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16911486</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.kashtan.2018.1045">Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, Nozu K, Renieri A, Rheault M, Wang F, Gross O. Alport syndrome: a unified classification of genetic disorders of collagen IV &#x003b1;345: a position paper of the Alport Syndrome Classification Working Group. <span><span class="ref-journal">Kidney Int. </span>2018;<span class="ref-vol">93</span>:1045–51.</span> [<a href="/pubmed/29551517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29551517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.kashtan.2013.5">Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. <span><span class="ref-journal">Pediatr Nephrol. </span>2013;<span class="ref-vol">28</span>:5–11.</span> [<a href="/pmc/articles/PMC3505543/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3505543</span></a>] [<a href="/pubmed/22461141" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22461141</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.kashtan.1996.142">Kashtan CE, Kleppel MM, Gubler MC. Immunohistologic findings in Alport syndrome. <span><span class="ref-journal">Contrib Nephrol. </span>1996;<span class="ref-vol">117</span>:142–53.</span> [<a href="/pubmed/8801043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8801043</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.kashtan.2010.3554">Kashtan CE, Segal Y, Flinter F, Makanjuola D, Gan JS, Watnick T. Aortic abnormalities in males with Alport syndrome. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2010;<span class="ref-vol">25</span>:3554–60.</span> [<a href="/pmc/articles/PMC2980995/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2980995</span></a>] [<a href="/pubmed/20494893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20494893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.king.2006.1061">King K, Flinter FA, Green PM. A two-tier approach to mutation detection in the COL4A5 gene for Alport syndrome. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:1061.</span> [<a href="/pubmed/16941480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16941480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.levy.2000.925">Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. <span><span class="ref-journal">Kidney Int. </span>2000;<span class="ref-vol">58</span>:925–43.</span> [<a href="/pubmed/10972657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10972657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.lyons.2007.816">Lyons OT, St. John ERC, Morales JP, Chan YC, Taylor PR. Ruptured thoracoabdominal aortic aneurysm in a renal transplant patient with Alport's syndrome. <span><span class="ref-journal">Ann Vasc Surg. </span>2007;<span class="ref-vol">21</span>:816–8.</span> [<a href="/pubmed/17697765" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17697765</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.mencarelli.2015.163">Mencarelli MA, Heidet L, Storey H, van Geel M, Knebelmann B, Fallerini C, Miglietti N, Antonucci MF, Cetta F, Sayer JA, van den Wijngaard A, Yau S, Mari F, Bruttini M, Ariani F, Dahan K, Smeets B, Antignac C, Flinter F, Renieri A. Evidence of digenic inheritance in Alport syndrome. <span><span class="ref-journal">J Med Genet. </span>2015;<span class="ref-vol">52</span>:163–74.</span> [<a href="/pubmed/25575550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25575550</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.merchant.2004.1609">Merchant SN, Burgess BJ, Adams JC, Kashtan CE, Gregory MC, Santi PA, Colvin R, Collins B, Nadol JB Jr. Temporal bone histopathology in Alport syndrome. <span><span class="ref-journal">Laryngoscope. </span>2004;<span class="ref-vol">114</span>:1609–18.</span> [<a href="/pubmed/15475791" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15475791</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.morini_re.2014.2740">Morini&#x000e8;re V, Dahan K, Hilbert P, Lison M, Lebbah S, Topa A, Bole-Feysot C, Pruvost S, Nitschke P, Plaisier E, Knebelmann B, Macher MA, Noel LH, Gubler MC, Antignac C, Heidet L. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. <span><span class="ref-journal">J Am Soc Nephrol. </span>2014;<span class="ref-vol">25</span>:2740–51.</span> [<a href="/pmc/articles/PMC4243343/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4243343</span></a>] [<a href="/pubmed/24854265" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24854265</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.mothes.2002.70">Mothes H, Heidet L, Arrondel C, Richter KK, Thiele M, Patzer L, Sado Y, Gubler MC, Antignac C, Scheele J. Alport syndrome associated with diffuse leiomyomatosis: COL4A5-COL4A6 deletion associated with a mild form of Alport nephropathy. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2002;<span class="ref-vol">17</span>:70–4.</span> [<a href="/pubmed/11773466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11773466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.nozu.2017.733">Nozu K, Minamikawa S, Yamada S, Oka M, Yanagita M, Morisada N, Fujinaga S, Nagano C, Gotoh Y, Takahashi E, Morishita T, Yamamura T, Ninchoji T, Kaito H, Morioka I, Nakanishi K, Vorechovsky I, Iijima K. Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis. <span><span class="ref-journal">J Hum Genet. </span>2017;<span class="ref-vol">62</span>:733–5.</span> [<a href="/pubmed/28275241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28275241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.oka.2014.1535">Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, Morisada N, Yan K, Matsuo M, Yoshikawa N, Vorechovsky I, Iijima K. Natural history of genetically proven autosomal recessive Alport syndrome. <span><span class="ref-journal">Pediatr Nephrol. </span>2014;<span class="ref-vol">29</span>:1535–44.</span> [<a href="/pubmed/24633401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24633401</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.okamoto.2019.155">Okamoto T, Nozu K, Iijima K, Ariga T. Germline mosaicism is a pitfall in the diagnosis of "sporadic" X-linked Alport syndrome. <span><span class="ref-journal">J Nephrol. </span>2019;<span class="ref-vol">32</span>:155–9.</span> [<a href="/pubmed/30062677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30062677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.plant.1999.124">Plant KE, Green PM, Vetrie D, Flinter FA. Detection of mutations in COL4A5 in patients with Alport syndrome. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">13</span>:124–32.</span> [<a href="/pubmed/10094548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10094548</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.renieri.1995.380">Renieri A, Galli L, Grillo A, Bruttini M, Neri T, Zanelli P, Rizzoni G, Massella L, Sessa A, Meroni M, Peratoner L, Riegler P, Scolari F, Mileti M, Giani M, Cossu M, Savi M, Ballabio A, De Marchi M. Major COL4A5 gene rearrangements in patients with juvenile type Alport syndrome. <span><span class="ref-journal">Am J Med Genet. </span>1995;<span class="ref-vol">59</span>:380–5.</span> [<a href="/pubmed/8599366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8599366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.savige.2018.1239">Savige J. Should we diagnose autosomal dominant Alport syndrome when there is a pathogenic heterozygous COL4A3 or COL4A4 variant? <span><span class="ref-journal">Kidney Int Rep. </span>2018;<span class="ref-vol">3</span>:1239–41.</span> [<a href="/pmc/articles/PMC6224634/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6224634</span></a>] [<a href="/pubmed/30450445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30450445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.storey.2013.1945">Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA. COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. <span><span class="ref-journal">J Am Soc Nephrol. </span>2013;<span class="ref-vol">24</span>:1945–54.</span> [<a href="/pmc/articles/PMC3839543/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3839543</span></a>] [<a href="/pubmed/24052634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24052634</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.van_der_loop.1999.1217">van der Loop FT, Monnens LA, Schroder CH, Lemmink HH, Breuning MH, Timmer ED, Smeets HJ. Identification of COL4A5 defects in Alport's syndrome by immunohistochemistry of skin. <span><span class="ref-journal">Kidney Int. </span>1999;<span class="ref-vol">55</span>:1217–24.</span> [<a href="/pubmed/10200983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10200983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alport.REF.zhou.1993.1167">Zhou J, Mochizuki T, Smeets H, Antignac C, Laurila P, de Paepe A, Tryggvason K, Reeders ST. Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. <span><span class="ref-journal">Science. </span>1993;<span class="ref-vol">261</span>:1167–9.</span> [<a href="/pubmed/8356449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8356449</span></a>]</div></li></ul></div></div><div id="alport.Chapter_Notes"><h2 id="_alport_Chapter_Notes_">Chapter Notes</h2><div id="alport.Author_Notes"><h3>Author Notes</h3><p><a href="http://experts.umn.edu/en/persons/clifford-kashtan(04043bb6-91b2-49d8-b16c-d9b2355c817a).html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dr Kashtan's website</a></p></div><div id="alport.Acknowledgments"><h3>Acknowledgments</h3><p>The author's work is supported by grants from the National Institutes of Health.</p></div><div id="alport.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>21 February 2019 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 November 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 February 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 July 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 January 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 January 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> for <i>COL4A5</i> clinically available</div></li><li class="half_rhythm"><div>26 September 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>29 December 2003 (ck) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> for COL4A5, COL4A3, COL4A4 clinically available; <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> available</div></li><li class="half_rhythm"><div>28 August 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 August 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>March 2001 (ck) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1207</span><span class="label">PMID: <a href="/pubmed/20301386" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301386</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/a-thal/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/alstrom/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1207&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1207/?report=reader">PubReader</a></li><li><a href="/books/NBK1207/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1207" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1207" style="display:none" title="Cite this Page"><div class="bk_tt">Kashtan CE. Alport Syndrome. 2001 Aug 28 [Updated 2019 Feb 21]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1207/pdf/Bookshelf_NBK1207.pdf">PDF version of this page</a> (510K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#alport.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#alport.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#alport.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#alport.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#alport.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#alport.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#alport.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#alport.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#alport.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#alport.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#alport.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1287[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">COL4A5</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1285[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">COL4A3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1286[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">COL4A4</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1207+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1462694" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1462694" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1462694" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1462694" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301541" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic Atypical Hemolytic-Uremic Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic Atypical Hemolytic-Uremic Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Noris M, Bresin E, Mele C, Remuzzi G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24398087" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">COL4A4-related nephropathy caused by a novel mutation in a large consanguineous Saudi family.</a><span class="source">[Int J Pediatr Otorhinolaryngol...]</span><div class="brieflinkpop offscreen_noflow">COL4A4-related nephropathy caused by a novel mutation in a large consanguineous Saudi family.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ramzan K, Imtiaz F, Taibah K, Alnufiee S, Akhtar M, Al-Hazzaa SA, Al-Owain M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Int J Pediatr Otorhinolaryngol. 2014 Mar; 78(3):427-32. Epub 2013 Dec 18.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28236514" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Familial hematuria: A review.</a><span class="source">[Medicina (Kaunas). 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Familial hematuria: A review.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Plevová P, Gut J, Janda J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Medicina (Kaunas). 2017; 53(1):1-10. Epub 2017 Jan 31.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30883042" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome.</a><span class="source">[Mol Genet Genomic Med. 2019]</span><div class="brieflinkpop offscreen_noflow">Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhang Y, Ding J, Zhang H, Yao Y, Xiao H, Wang S, Wang F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Genet Genomic Med. 2019 May; 7(5):e647. Epub 2019 Mar 18.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19728970" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Alport syndrome. Molecular genetic aspects.</a><span class="source">[Dan Med Bull. 2009]</span><div class="brieflinkpop offscreen_noflow">Alport syndrome. Molecular genetic aspects.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hertz JM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Dan Med Bull. 2009 Aug; 56(3):105-52. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301386" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301386" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04172a75f66d18aa6b922e">Alport Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Alport Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:12:58-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE8973CBE03FE041000000000B5A04E2&amp;ncbi_session=CE8973CBE0417291_2906SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1207%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1207&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1207/&amp;ncbi_pagename=Alport Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8973CBE0417291_2906SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>